All In Biotech

Drug Trial Radar · NCT02689583

A Multi-center Study for Individual Treatment of Helicobacter Pylori Infection

Last checked: Nov 19, 2026Latest source record: Feb 24, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 3,000 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

3,000

Planned (sponsor's estimate)

Start

Mar 2016

Primary completion

Mar 2017

Sponsor

Lead sponsor
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Peking Union Medical College Hospital; Nanfang Hospital, Southern Medical University; Third Affiliated Hospital of Third Military Medical University; The First Affiliated Hospital with Nanjing Medical University; Centers for Disease Control and Prevention, China; Academy Military Medical Science, China
First posted
Feb 24, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Since the discovery of Helicobacter pylori (H. pylori), many studies have been carried out with the goal of improving H. pylori eradication and therapies have changed from single-antibiotic treatments to the current multi-antibiotic treatments. However, the eradication rate of H. pylori is still less than 80%. The reasons for this low eradication rate are likely to be multi-factorial, including the reduced activity of antimicrobial drugs, poor patient compliance or micro-environment in stomach. In this study, to obtain the higher eradication of H. pylori and discover the different mechanism between the current infection and refractory infection of H. pylori, it is necessary to perform a prevalence survey for eradication of H. pylori based on the results from isolation of H. pylori strains, antibiotic susceptibility testing, CYP2C19 gene polymorphism, drug resistance gene sequencing and 16SrRNA sequencing.

Conditions

  • Gastritis
  • Gastric Ulcer

Interventions

  • Antibiotic selection based on the antibiotic susceptibility testingBiological

    The biological intervention focused on the results from the antibiotic susceptibility testing. All patients should used the their susceptibility antibiotics according to antibiotic susceptibility testing of H. pylori. Considering the safety of drug usage, priority antibiotic selection was as follow: Amoxicillin \> Clarithromycin \> Levofloxacin \>Tetracycline \> Furazolidone \> Metronidazole.

  • PPI selection based on the CYP2C19 gene polymorphismGenetic

    PPI selection should based on the CYP2C19 gene polymorphism of patients. Patients have different metabolizers, such as poor metabolizers (PM), extensive metabolizers (EM) and intermediate metabolizer (IM). Different metabolism of patients should select different PPI or different doses of PPI. For IM and PM, in this study, patients selected the standard dose of Omeprazole. For EM, in this study, patients selected the Esomeprazole with increasing doses 50%-100%.

  • Probiotics usage based on the 16SrRNA sequencingDietary supplement

    Different micro-environment in stomach may influence the antibiotic absorption. In this study, some patients could select probiotic as adjuvant therapy according to their micro-environment in stomach by 16SrRNA sequencing.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Eradication ratesTime frame: Three months
  2. Mutation site of drug resistance geneTime frame: Three months
  3. The distribution and proportion of microflora in stomachTime frame: Three months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.